Castellano | Euskara | Français | English
DAR No 2. Apixaban. Eliquis® for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation
Share it
Now we have three anticoagulants where the degree of anticoagulation is unknown
- This is an oral anticoagulant that lacks an antidote, and does not require INR monitoring which implies uncertainty with regard to the degree of anticoagulation.
- In one trial, apixaban showed superiority when compared to warfarin in the composite primary endpoint of stroke or systemic embolism. However, this superiority was not observed in patients with adequate INR control under warfarin.
- It presented a lower incidence of severe bleeding compared to warfarin and no differences in relation to gastrointestinal bleeding.
- No comparative studies are available versus acenocumarol, dabigatran or rivaroxaban and its long-term safety profile is unknown.
- Apixaban, dabigatran and rivaroxaban are only alternatives to vitamin K antagonists when it is not possible to achieve adequate anticoagulation.
